Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.13 -1.49%
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- UBS Reiterates Buy Rating on Expeditors Int'l (EXPD)
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
